Clinical trials
Progression clinical trials
Below are recruiting progression clinical trials, each written for real people, not researchers. We’re tracking 719 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05272371RecruitingPhase 1
Dinutuximab beta plus chemo for childhood neuroblastoma after relapse
This Phase 1 trial tests a combination of dinutuximab beta (an immunotherapy) and chemotherapy in children with high-risk neuroblastoma that did not respond to standard treatment or has come back or progressed. It aims to see how well the treatment works and how safely it can be given in this situation.
Krakow, MalopolskaAges 1–18 - NCT05392699RecruitingPhase 1
Testing ABOD2011 for advanced solid tumors after standard treatment
This Phase 1 trial tests a new medicine (ABOD2011) in people with advanced solid tumors that have come back or spread after standard treatment. It may help by shrinking tumors and allows researchers to study the tumor by giving medicine directly into it and taking a biopsy.
BeijingAges 18 years+ - NCT04893785RecruitingPhase 2
Cabozantinib plus temozolomide for advanced neuroendocrine lung tumors
This Phase 2 study tests whether combining cabozantinib with temozolomide can control advanced lung or gastrointestinal neuroendocrine tumors that have grown after prior treatments. It also closely monitors safety, including blood counts, organ function, and other side effects.
Naples, CampaniaAges 18 years+ - NCT04723888Recruiting
Supplements to slow aneurysm growth and prevent rupture
This trial studies whether alpha-ketoglutarate, a supplement, can slow the growth of an abdominal aortic aneurysm and reduce the risk of rupture. It may help people whose aneurysm size is in a specific range by tracking changes over time and watching for safety.
ShanghaiAges 50 years+ - NCT04819217Recruiting
Probiotics and a toxin binder to slow chronic kidney disease
This trial studies an oral product (a “uremic toxin” absorber) plus probiotics to help slow the progression of chronic kidney disease. It may help by lowering harmful gut-related substances that can build up when kidney function is reduced.
TaipeiAges 20 years+ - NCT04762641RecruitingPhase 1
First-dose safety study of ABL503 for advanced cancers
This Phase 1 trial tests the safety and side effects of ABL503 and finds the best dose to study next. It is for people with advanced cancer that is growing despite prior treatment options.
Duarte, CaliforniaAges 18 years+ - NCT04775485RecruitingPhase 2
Targeted medicine for children with certain brain or solid tumors
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
San Francisco, CaliforniaAges 6 months–25 years - NCT04805437Recruiting
Brace treatment for early idiopathic scoliosis in kids
This study tests whether wearing a scoliosis brace can stop or slow curve worsening in children who are still growing. It is meant for kids with a moderate, idiopathic (not caused by another condition) curve.
LinköpingAges 9–17 - NCT04966481RecruitingPhase 3
Palbociclib plus cetuximab versus cetuximab alone
This trial studies whether adding palbociclib to cetuximab works better than cetuximab by itself for head and neck cancer that is growing again after an anti–PD-1/PD-L1 treatment. It is for people whose tumor has a specific gene change (CDKN2A loss) and who have not had too many prior treatments.
Worthington, MinnesotaAges 18 years+ - NCT05533983Recruiting
Stool transplant plus nivolumab for advanced solid cancers
This study tests whether transferring stool microbiome (“FMT,” stool transplant) along with nivolumab can improve outcomes in people with advanced solid cancers that kept worsening even after anti–PD-1/PD-L1 treatment. It also looks at stool and blood changes to understand why the treatment might work.
SeoulAges 19 years+ - NCT02363595Recruiting
Genetic clues for how small thyroid cancers may grow
This study looks at gene changes to predict whether a small papillary thyroid cancer found on biopsy is likely to stay stable or grow over time. It may help doctors choose who can safely stay on watchful waiting.
New York, New YorkAges 18 years+ - NCT05689034RecruitingPhase 2/Phase 3
Azvudine for early COVID-19 in higher-risk adults
This trial studies azvudine in adults with early COVID-19 symptoms to see if it can prevent the illness from getting severe. You may qualify if you’re within about 5 days of symptom start and have risk factors for worsening disease.
Beijing, Beijing MunicipalityAges 18–120 - NCT06529549Recruiting
Organoid drug test for advanced prostate cancer
This trial uses a lab test on a tiny sample of your tumor (called an organoid) to find which drug might work best for your advanced prostate cancer. It's for men whose cancer has stopped responding to hormone therapy and got worse after first treatment.
Guangzhou, GuangdongAges 18–75 - NCT06167785RecruitingPhase 2
Study of zanubrutinib and tislelizumab for lymphoma after CAR-T
This trial tests two new drugs (zanubrutinib and tislelizumab) for people with large B-cell lymphoma that has come back or not responded after CAR-T therapy. The goal is to see if these drugs can help when CAR-T hasn't worked.
Toronto, OntarioAges 18 years+ - NCT04581122Recruiting
Tests how lymph node surgery choices affect lung nodule outcomes
This study looks at whether different lymph node removal methods during lung surgery change outcomes for certain abnormal lung spots. It focuses on ground-glass nodules that stay the same after treatment-free observation and have a mostly solid portion on CT.
ShanghaiAges 18–75 - NCT06751901RecruitingPhase 2
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized peptide vaccine, an immunotherapy drug (PD-1 inhibitor), and radiation for people with advanced non-small cell lung cancer whose disease has gotten worse after at least two standard treatments. It aims to see if this triple therapy can help control the cancer.
Nanchang, JiangxiAges 18–70 - NCT06338683RecruitingPhase 3
Olanzapine for advanced upper digestive and lung cancer survival
This study tests whether a medicine called olanzapine can improve survival in people with advanced cancers of the upper digestive system or lungs. Olanzapine may help with appetite and weight, which are common problems in these cancers.
Xining, QinghaiAges 18–80 - NCT03650673Recruiting
Study of early finger osteoarthritis symptoms over time
This study follows people with early finger (hand) osteoarthritis symptoms to better understand how the condition starts and changes. You may be asked for blood tests, symptom checks, and imaging to see what’s happening in the joints.
MontpellierAges 18–60 - NCT04905056RecruitingPhase 2
Ablation treatment for lung ground-glass nodules that don’t go away
This Phase 2 trial studies whether a procedure called “ablation” is safe and effective for certain lung cancers that appear as ground-glass spots on CT scans and do not improve after 3 months. It may help people who cannot fully have surgery for their condition.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT06752044Recruiting
Vaccine, immunotherapy, and radiation for advanced lung cancer
This trial tests a combination of a personalized vaccine (made from your tumor's unique markers), a drug that boosts your immune system (PD-1 inhibitor), and targeted radiation for people with advanced lung cancer that has progressed after initial treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Nanchang, JiangxiAges 18–70 - NCT07679477Enrolling by invitation
Myopia control study for university students with special glasses
This study tests whether special spectacle lenses (called DIMS-TED) can slow down the progression of myopia (nearsightedness) in university students. It is for students whose eyes are still growing and who are willing to wear the glasses as assigned.
Bradford, West YorkshireAges 18–23 - NCT07651540Recruiting
Understanding Sensory Nerve Damage: The Neuronoscore Study
This study helps doctors better understand and measure sensory nerve damage (nerves that feel pain, temperature, and touch). You may qualify if you have a specific type of nerve damage caused by cancer, autoimmune disease, platinum chemotherapy, or a rare genetic condition.
AngersAges 18 years+ - NCT06444412RecruitingPhase 2
Testing a new PET scan to detect brain tumor recurrence
This trial tests a special imaging scan called Ga-68 PSMA-11 PET/CT to see if it can better detect when a glioma brain tumor has come back or progressed. It is for people who have already had standard treatment and are planning surgery for a suspected recurrence.
Rochester, MinnesotaAges 18 years+ - NCT06378892RecruitingPhase 2
Study of chemo plus lorlatinib for ALK+ lung cancer
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
AvianoAges 18 years+
Hear when a new Progression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for progression?
- Yes. Clin2 currently lists 719 recruiting progression studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a progression trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a progression trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.